이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

전신성 홍반성 루푸스 환자를 대상으로 한 다피로리주맙 페골의 안전성 및 내약성 평가를 위한 연구

2026년 11월 9일 업데이트: UCB Biopharma SRL

전신성 홍반성 루푸스 환자를 대상으로 다피롤리주맙 페골 치료의 장기 안전성 및 내약성을 평가하기 위한 다기관 공개 확장 연구

The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.

연구 개요

상태

초대로 등록

연구 유형

중재적

등록 (추정된)

760

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Athens, 그리스
        • Sl0046 40378
      • Athens, 그리스
        • Sl0046 40501
      • Crete, 그리스
        • Sl0046 40377
      • Larissa, 그리스
        • Sl0046 40507
      • Taichung, 대만
        • Sl0046 20113
      • Taichung, 대만
        • Sl0046 20142
      • Taipei, 대만
        • Sl0046 20095
      • Taiyuan, 대만
        • Sl0046 20082
      • Incheon, 대한민국
        • Sl0046 20108
      • Seoul, 대한민국
        • Sl0046 20104
      • Cologne, 독일
        • Sl0046 40386
      • Freiburg im Breisgau, 독일
        • Sl0046 40072
      • Herne, 독일
        • Sl0046 40027
      • Leipzig, 독일
        • Sl0046 40078
      • Tübingen, 독일
        • Sl0046 40402
      • Vogelsang-gommern, 독일
        • Sl0046 40715
      • Galati, 루마니아
        • Sl0046 40382
      • Chihuahua City, 멕시코
        • Sl0046 50317
      • Cuernavaca, 멕시코
        • Sl0046 50250
      • Guadalajara, 멕시코
        • Sl0046 50249
      • León, 멕시코
        • Sl0046 50271
      • Monterrey, 멕시코
        • Sl0046 50251
      • Mérida, 멕시코
        • Sl0046 50252
    • Alabama
      • Birmingham, Alabama, 미국, 35294
        • Sl0046 50140
    • Arizona
      • Avondale, Arizona, 미국, 85392
        • Sl0046 50058
      • Glendale, Arizona, 미국, 85306
        • Sl0046 50662
      • Phoenix, Arizona, 미국, 85032
        • Sl0046 50052
      • Tucson, Arizona, 미국, 85704
        • Sl0046 50328
    • California
      • Beverly Hills, California, 미국, 90210
        • Sl0046 50383
      • La Palma, California, 미국, 90623-1730
        • Sl0046 50275
      • San Leandro, California, 미국, 94578
        • Sl0046 50316
    • Colorado
      • Denver, Colorado, 미국, 80230
        • Sl0046 50339
    • Florida
      • Brandon, Florida, 미국, 33511
        • Sl0046 50239
      • Gainesville, Florida, 미국, 32610
        • Sl0046 50362
      • Miami, Florida, 미국, 33172
        • Sl0046 50681
      • Ormond Beach, Florida, 미국, 32174
        • Sl0046 50059
      • Plantation, Florida, 미국, 33324
        • Sl0046 50324
      • Tampa, Florida, 미국, 33606
        • Sl0046 50329
      • Tampa, Florida, 미국, 33618
        • Sl0046 50698
    • Georgia
      • Atlanta, Georgia, 미국, 30303
        • Sl0046 50368
    • Idaho
      • Idaho Falls, Idaho, 미국, 83404
        • Sl0046 50240
    • Illinois
      • Chicago, Illinois, 미국, 60616
        • Sl0046 50699
    • Kentucky
      • Hopkinsville, Kentucky, 미국, 42240-1746
        • Sl0046 50474
    • Louisiana
      • Lake Charles, Louisiana, 미국, 70605
        • Sl0046 50285
      • New Orleans, Louisiana, 미국, 70112
        • Sl0046 50660
    • Maryland
      • Hagerstown, Maryland, 미국, 21740
        • Sl0046 50015
    • Michigan
      • Detroit, Michigan, 미국, 48201
        • Sl0046 50219
    • Nevada
      • Las Vegas, Nevada, 미국, 89128
        • Sl0046 50273
    • New York
      • Canton, New York, 미국, 13617
        • Sl0046 50366
      • Manhasset, New York, 미국, 11030
        • Sl0046 50264
      • New York, New York, 미국, 10032
        • Sl0046 50334
    • North Carolina
      • Charlotte, North Carolina, 미국, 28211
        • Sl0046 50238
    • Pennsylvania
      • Hershey, Pennsylvania, 미국, 17033
        • Sl0046 50147
    • Tennessee
      • Jackson, Tennessee, 미국, 38305
        • Sl0046 50001
    • Texas
      • Bellaire, Texas, 미국, 77401
        • Sl0046 50738
      • Colleyville, Texas, 미국, 76034
        • Sl0046 50418
    • West Virginia
      • Beckley, West Virginia, 미국, 25801
        • Sl0046 50050
      • Brussels, 벨기에
        • Sl0046 40123
      • Plovdiv, 불가리아
        • Sl0046 40189
      • Sofia, 불가리아
        • Sl0046 40380
      • Belgrade, 세르비아
        • Sl0046 40393
      • Belgrade, 세르비아
        • Sl0046 40461
      • Belgrade, 세르비아
        • Sl0046 40730
      • Novi Sad, 세르비아
        • Sl0046 40392
      • Barcelona, 스페인
        • Sl0046 40160
      • Málaga, 스페인
        • Sl0046 40341
      • Sabadell, 스페인
        • Sl0046 40101
      • Vigo, 스페인
        • Sl0046 40099
      • Buenos Aires, 아르헨티나
        • Sl0046 60002
      • Mendoza, 아르헨티나
        • Sl0046 60029
      • Quilmes, 아르헨티나
        • Sl0046 60003
      • Quilmes, 아르헨티나
        • Sl0046 60022
      • San Juan, 아르헨티나
        • Sl0046 60011
      • San Miguel de Tucumán, 아르헨티나
        • Sl0046 60014
      • Catania, 이탈리아
        • Sl0046 40084
      • Milan, 이탈리아
        • Sl0046 40448
      • Nagoya, 일본
        • Sl0046 20287
      • Beijing, 중국
        • Sl0046 20128
      • Changchun, 중국
        • Sl0046 20291
      • Guangzhou, 중국
        • Sl0046 20019
      • Guilin, 중국
        • Sl0046 20290
      • Shanghai, 중국
        • Sl0046 20020
      • Shantou, 중국
        • Sl0046 20346
      • Suzhou, 중국
        • Sl0046 20204
      • Tianjin, 중국
        • Sl0046 20136
      • Wenzhou, 중국
        • Sl0046 20025
      • Wuhan, 중국
        • Sl0046 20180
      • Yangzhou, 중국
        • Sl0046 20273
      • Zhengzhou, 중국
        • Sl0046 20132
      • Prague, 체코
        • Sl0046 40066
      • Santiago, 칠레
        • Sl0046 60018
      • Santiago, 칠레
        • Sl0046 60015
      • Calgary, 캐나다
        • Sl0046 50374
      • Edmonton AB, 캐나다
        • Sl0046 50337
      • Rimouski, 캐나다
        • Sl0046 50259
      • Toronto, 캐나다
        • Sl0046 50045
      • Barranquilla, 콜롬비아
        • Sl0046 60013
      • Barranquilla, 콜롬비아
        • Sl0046 60019
      • Bogotá, 콜롬비아
        • Sl0046 60006
      • Bogotá, 콜롬비아
        • Sl0046 60027
      • Bucaramanga, 콜롬비아
        • Sl0046 60016
      • Chía, 콜롬비아
        • Sl0046 60007
      • Montería, 콜롬비아
        • Sl0046 60031
      • Lima, 페루
        • Sl0046 60023
      • Lima, 페루
        • Sl0046 60009
      • Bialystok, 폴란드
        • Sl0046 40482
      • Bydgoszcz, 폴란드
        • Sl0046 40119
      • Katowice, 폴란드
        • Sl0046 40398
      • Krakow, 폴란드
        • Sl0046 40502
      • Lublin, 폴란드
        • Sl0046 40151
      • Poznan, 폴란드
        • Sl0046 40044
      • Poznan, 폴란드
        • Sl0046 40090
      • Warsaw, 폴란드
        • Sl0046 40097
      • Warsaw, 폴란드
        • Sl0046 40098
      • Wroclaw, 폴란드
        • Sl0046 40397
      • Wroclaw, 폴란드
        • Sl0046 40481
      • Caguas, 푸에르토 리코
        • Sl0046 50671
      • Davao City, 필리핀 제도
        • Sl0046 20182
      • Makati, 필리핀 제도
        • Sl0046 20181
      • Budapest, 헝가리
        • Sl0046 40412
      • Debrecen, 헝가리
        • Sl0046 40411
      • Szeged, 헝가리
        • Sl0046 40031
      • Székesfehérvár, 헝가리
        • Sl0046 40499

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

16년 이상 (어린이, 성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • The participant could, in the opinion of the Investigator, benefit from long-term dapirolizumab pegol (DZP) treatment
  • The participant completed one of the parent studies within 4 weeks prior to entry to this study

Exclusion Criteria:

- Study participant has any medical or psychiatric condition (including conditions due to neuropsychiatric systemic lupus erythematosus (SLE)) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study. This includes study participants with a life-threatening condition or ongoing malignancies at the start of the study

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Dapirolizumab pegol

Subjects will receive dapriolizumab pegol throughout the Treatment Period.

Subjects will receive dapirolizumab pegol at prespecified time-points.

다른 이름들:
  • CDP7657
  • DZP

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Incidence of treatment-emergent adverse events (TEAEs) during the study
기간: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)

Treatment-emergent adverse events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment.

From Baseline (Day 1) until Safety Follow-Up (up to Week 110)
Incidence of serious treatment-emergent adverse events during the study
기간: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)

A serious treatment-emergent adverse event (serious TEAE) is any untoward medical occurrence that at any dose:

  • Results in death
  • Is life-threatening
  • Requires in patient hospitalisation or prolongation of existing hospitalisation
  • Results in persistent disability/incapacity
  • Is a congenital anomaly or birth defect
  • Other important medical events which based on medical or scientific judgement may jeopardise the patients, or may require medical or surgical intervention to prevent any of the above
From Baseline (Day 1) until Safety Follow-Up (up to Week 110)
Incidence of treatment-emergent adverse events (TEAEs) leading to permanent dapirolizumab pegol discontinuation
기간: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)

Treatment-emergent adverse events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, and leading to permanent drug discontinuation whether or not these events are related to study treatment.

From Baseline (Day 1) until Safety Follow-Up (up to Week 110)

2차 결과 측정

결과 측정
측정값 설명
기간
Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 24
기간: Week 24

BILAG severe flare is defined as a new British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade A in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010).

Week 24
Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 48
기간: Week 48

BILAG severe flare is defined as a new British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade A in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010).

Week 48
Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 104
기간: Week 104

BILAG severe flare is defined as a new British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade A in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010).

Week 104
Achievement of LLDAS at Week 48
기간: Week 48

Low lupus disease activity state (LLDAS) is defined as:

  • No significant disease activity as per SLEDAI-2K (SLEDAI-2K score ≤4 with no activity in major organ systems (renal, central nervous system (CNS), cardiopulmonary, vasculitis, fever)
  • No new and/or worsening disease activity defined as no SLEDAI-2K component documented as present that was not documented present at previous visit
  • PGA ≤33 mm
  • Prednisone equivalent systemic dose for systemic lupus erythematosus (SLE) indication ≤7.5 mg per day
  • Stable standard maintenance doses of immunosuppressive drugs as allowed by protocol
Week 48
Achievement of LLDAS at Week 104
기간: Week 104

Low lupus disease activity state (LLDAS) is defined as:

  • No significant disease activity as per SLEDAI-2K (SLEDAI-2K score ≤4 with no activity in major organ systems (renal, central nervous system (CNS), cardiopulmonary, vasculitis, fever)
  • No new and/or worsening disease activity defined as no SLEDAI-2K component documented as present that was not documented present at previous visit
  • PGA ≤33 mm
  • Prednisone equivalent systemic dose for systemic lupus erythematosus (SLE) indication ≤7.5 mg per day
  • Stable standard maintenance doses of immunosuppressive drugs as allowed by protocol
Week 104
Achievement of BICLA response at Week 48 (using the parent study baseline as the reference point)
기간: Week 48

A study participant is considered to be a BILAG 2004-based Composite Lupus Assessment (BICLA) responder if all of the following is fulfilled:

  1. British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤1 new B.); and
  2. No worsening in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and
  3. No worsening in the Physician's Global Assessment of Disease (PGA) compared to Baseline Visit defined as ≤10 mm increase on a 100 mm visual analog scale
Week 48
Achievement of BICLA response at Week 104 (using the parent study baseline as the reference point)
기간: Week 104

A study participant is considered to be a BICLA responder if all of the following is fulfilled:

  1. BILAG 2004 improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤1 new B.); and
  2. No worsening in the SLEDAI-2K total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and
  3. No worsening in the PGA compared to Baseline Visit defined as ≤10 mm increase on a 100 mm visual analog scale
Week 104
Achievement of SRI-4 response at Week 48 (using the parent study baseline as the reference point)
기간: Week 48

The Systemic Lupus Erythematosus Responder Index-4 (SRI 4) define responders as (ie, all criteria must be met):

  • Reduction in SLEDAI-2K score of ≥4
  • No shift from BILAG 2004 Grade B, C, D, or E to A post-Baseline
  • No more than 1 shift from BILAG 2004 Grade C, D, or E to B post-Baseline
  • No worsening in the PGA compared to Baseline Visit defined as ≤10 mm increase on a 100 mm visual analog scale.
Week 48
Achievement of SRI-4 response at Week 104 (using the parent study baseline as the reference point)
기간: Week 104

The Systemic Lupus Erythematosus Responder Index-4 (SRI 4) define responders as (ie, all criteria must be met):

  • Reduction in SLEDAI-2K score of ≥4
  • No shift from BILAG 2004 Grade B, C, D, or E to A post-Baseline
  • No more than 1 shift from BILAG 2004 Grade C, D, or E to B post-Baseline
  • No worsening in the PGA compared to Baseline Visit defined as ≤10 mm increase on a 100 mm visual analog scale.
Week 104
Change from parent study Baseline in FATIGUE-PRO Total score at Week 48
기간: From Baseline to Week 48

The FATIGUE-PRO (Fatigue patient-reported outcome) is a PRO instrument measuring fatigue, a core symptom of SLE, developed using qualitative and quantitative research conducted in patients with SLE. It is composed of 31 items covering 3 domains: Physical Fatigue (items 1-9), Mental and Cognitive Fatigue (items 10-20), and Susceptibility to Fatigue (items 21-31). The study participant is asked to score each fatigue item based on how frequently they experienced the item during the past 7 days using the following response options: 1=none of the time; 2=a little of the time; 3=some of the time; 4=most of the time; 5=all of the time. Responses to the FATIGUE PRO questions allow calculation of 4 scores: a Total score assessing overall fatigue and a score for each of the 3 domains, all ranging from 0 to 100, with higher scores indicating higher levels of fatigue.

From Baseline to Week 48
Change from parent study Baseline in FATIGUE-PRO Total score at Week 104
기간: From Baseline to Week 104

The FATIGUE-PRO (Fatigue patient-reported outcome) is a PRO instrument measuring fatigue, a core symptom of SLE, developed using qualitative and quantitative research conducted in patients with SLE. It is composed of 31 items covering 3 domains: Physical Fatigue (items 1-9), Mental and Cognitive Fatigue (items 10-20), and Susceptibility to Fatigue (items 21-31). The study participant is asked to score each fatigue item based on how frequently they experienced the item during the past 7 days using the following response options: 1=none of the time; 2=a little of the time; 3=some of the time; 4=most of the time; 5=all of the time. Responses to the FATIGUE PRO questions allow calculation of 4 scores: a Total score assessing overall fatigue and a score for each of the 3 domains, all ranging from 0 to 100, with higher scores indicating higher levels of fatigue.

From Baseline to Week 104
Percentage of participants having a reduction in glucocorticoid dose from >7.5mg/day prednisone-equivalent dose at the parent study Baseline to ≤7.5mg/day at Week 48
기간: From Baseline to Week 48

The achievement of a reduction in glucocorticoid dose from >7.5mg/day prednisone equivalent dose at the parent study Baseline to ≤7.5mg/day prednisone equivalent at Week 48

From Baseline to Week 48
Percentage of participants having a reduction in glucocorticoid dose from >7.5mg/day prednisone-equivalent dose at the parent study Baseline to ≤7.5mg/day at Week 104
기간: From Baseline to Week 104

The achievement of a reduction in glucocorticoid dose from >7.5mg/day prednisone equivalent dose at the parent study Baseline to ≤7.5mg/day prednisone equivalent at Week 104

From Baseline to Week 104

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: UCB Cares, 001 844 599 2273 (UCB)

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 7월 27일

기본 완료 (추정된)

2030년 8월 7일

연구 완료 (추정된)

2030년 8월 7일

연구 등록 날짜

최초 제출

2021년 7월 14일

QC 기준을 충족하는 최초 제출

2021년 7월 14일

처음 게시됨 (실제)

2021년 7월 26일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 13일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 9일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • SL0046
  • 2019-003409-83 (EudraCT 번호)
  • U1111-1293-7098 (기타 식별자: World Health Organization (WHO))
  • 2023-506368-14 (레지스트리 식별자: EU Clinical Trials)
  • 2023 (미국 NIH 보조금/계약)
  • 2019 (미국 NIH 보조금/계약)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

IPD 공유 기간

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

IPD 공유 액세스 기준

Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다